New Study Shows Utility of Masimo rainbow Acoustic Monitoring
January 21, 2016 08:03 AM Eastern Standard Time
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today that in a new study that compared acoustic respiration rate (RRa®) from Masimo's rainbow® Acoustic Monitoring (RAMTM) to respiration rate from conventional capnography, researchers concluded that RAM was useful for monitoring dental patients under intravenous anesthesia.1
The Anesthesia Patient Safety Foundation (APSF) and The Joint Commission recommend continuous oxygenation and ventilation monitoring in all patients receiving opioid-based pain medications.² RAM noninvasively and continuously measures respiration rate using an innovative adhesive sensor with an integrated acoustic transducer that is easily and comfortably applied to the patient's neck.
The study, published in the Journal of Clinical Monitoring and Computing by Dr. Kentaro Ouchi and colleagues from Japan, compared the respiration rate measurements from RAM and capnography (Psychorich IS nasal cannula and BP-608 Omron Colin monitor) in non-intubated patients with dental anxiety undergoing dental treatment. A total of 1953 data points of respiratory rate were taken from the start to the end of anesthesia. Over the entire observation period, the results showed a significantly higher detection of respiratory rate by RAM (1884 points, 96.5%) than by capnography (1682 points, 86.1%) P < 0.0001. When comparing respiration rate from RAM and capnography during the induction, intraoperative, and emergence periods, the 95% limits of agreement (LOA) were -7.4 to 6.7 , -5.4 to 7.0, -3.9 to 5.3, respectively. The researchers commented that this study was only a comparison between two devices, since neither method could be considered a "corrective control," or gold-standard reference.
The authors concluded, "In comparison between capnography using a nasal cannula for continuous monitoring for the respiratory rate, the acoustic method is useful during intravenous general anesthesia in unintubated spontaneously breathing patients undergoing dental procedures." The authors note that the acoustic method might not accurately detect respiratory rate in cases in which a dental air turbine is used.
For more information on the RAM Acoustic Respiratory Rate Monitoring System, go to www.masimo.com.
@MasimoInnovates | #Masimo
1 Ouchi (et al.), Acoustic Method Respiratory Rate Monitoring is Useful in Patients Under Intravenous Anesthesia. J Clin Monit Comput 2016; published online.
2 Stoelting, RK et al. APSF newsletter. 2011. www.apsf.org.
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. The benefits of Masimo SET® have been proven in more than 100 independent and objective studies and it is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index (ORI™), in addition to SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive open architecture patient monitoring and connectivity platform designed to speed the pace of innovation and reduce the cost of care. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results or studies; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo's rainbow® Acoustic Monitoring (RAMTM) contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation, including the dental setting; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Irene Paigah, 858-859-7001